Long-term, Prospective, Observational, Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying Therapy

Trial Profile

Long-term, Prospective, Observational, Multinational, Parallel-cohort Study Monitoring Safety in Patients With MS Newly Started With Fingolimod Once Daily or Treated With Another Approved Disease-modifying Therapy

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 26 Feb 2018

At a glance

  • Drugs Fingolimod (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms PASSAGE
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 21 Feb 2018 Planned number of patients changed from 3600 to 3620.
    • 28 Oct 2017 Results assessing efficacy of fingolimod in RRMS patients who switched from first-line oral DMTs vs patients who switched directly from injectable DMTs using data from PASSAGE and PANGAEA trials presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 03 Mar 2017 Planned End Date changed from 1 Jun 2020 to 28 Nov 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top